Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 Mar 28. doi: 10.1158/1535-7163.MCT-17-0302. [Epub ahead of print]

PMID:
29592880
2.

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.

Stebbing J, Baranau Y, Manikhas A, Lee SJ, Thiruchelvam P, Leff D, Esteva FJ.

Expert Rev Anticancer Ther. 2018 Apr 2:1-11. doi: 10.1080/14737140.2018.1457442. [Epub ahead of print]

PMID:
29580109
3.

Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.

Khodadadi-Jamayran A, Akgol-Oksuz B, Afanasyeva Y, Heguy A, Thompson M, Ray K, Giro-Perafita A, Sánchez I, Wu X, Tripathy D, Zeleniuch-Jacquotte A, Tsirigos A, Esteva FJ.

Oncotarget. 2018 Feb 5;9(16):12868-12878. doi: 10.18632/oncotarget.24403. eCollection 2018 Feb 27.

4.

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

Esteva FJ, Saeki T, Kim H, Stebbing J.

Future Oncol. 2018 Feb 27. doi: 10.2217/fon-2017-0679. [Epub ahead of print]

PMID:
29482364
5.

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.

Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ, Ryvo L, Lopez R, Tsai M, Esteva FJ, Auñón PZ, Kral Z, Ward P, Richards P, Pluard TJ, Sutradhar S, Miller M, Campone M.

Breast Cancer Res Treat. 2018 Feb 5. doi: 10.1007/s10549-017-4658-x. [Epub ahead of print]

PMID:
29404806
6.

A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.

Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY, Lee SJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):505-514. doi: 10.1007/s00280-017-3510-7. Epub 2018 Jan 12.

7.

DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.

Menyhart O, Budczies J, Munkácsy G, Esteva FJ, Szabó A, Miquel TP, Győrffy B.

Oncotarget. 2017 Aug 24;8(44):77207-77218. doi: 10.18632/oncotarget.20430. eCollection 2017 Sep 29.

8.

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.

Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S.

Breast Cancer Res. 2017 Aug 2;19(1):89. doi: 10.1186/s13058-017-0879-5.

9.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ.

Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4.

10.

Clinical utility of gene-expression signatures in early stage breast cancer.

Kwa M, Makris A, Esteva FJ.

Nat Rev Clin Oncol. 2017 Oct;14(10):595-610. doi: 10.1038/nrclinonc.2017.74. Epub 2017 May 31. Review.

PMID:
28561071
11.

Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.

Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw314.

PMID:
28376179
12.

RNF11 sequestration of the E3 ligase SMURF2 on membranes antagonizes SMAD7 down-regulation of transforming growth factor β signaling.

Malonis RJ, Fu W, Jelcic MJ, Thompson M, Canter BS, Tsikitis M, Esteva FJ, Sánchez I.

J Biol Chem. 2017 May 5;292(18):7435-7451. doi: 10.1074/jbc.M117.783662. Epub 2017 Mar 14.

PMID:
28292929
13.

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.

de Oliveira Taveira M, Nabavi S, Wang Y, Tonellato P, Esteva FJ, Cantley LC, Wulf GM.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1255-1262. doi: 10.1007/s00432-017-2358-x. Epub 2017 Feb 28.

14.

Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.

Johanning GL, Malouf GG, Zheng X, Esteva FJ, Weinstein JN, Wang-Johanning F, Su X.

Sci Rep. 2017 Feb 6;7:41960. doi: 10.1038/srep41960.

15.

Biosimilars: Here and Now.

Lemery SJ, Esteva FJ, Weise M.

Am Soc Clin Oncol Educ Book. 2016;35:e151-7. doi: 10.14694/EDBK_155954.

16.

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ.

Clin Breast Cancer. 2016 Apr;16(2):113-22.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1.

17.

Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma.

Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK.

Br J Cancer. 2015 Sep 29;113(7):1003-9. doi: 10.1038/bjc.2015.308. Epub 2015 Sep 22.

18.

Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Teplinsky E, Esteva FJ.

Curr Oncol Rep. 2015 Oct;17(10):46. doi: 10.1007/s11912-015-0471-z. Review.

PMID:
26314739
19.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

20.
21.

What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?

Esteva FJ, Miller KD, Teicher BA.

Am Soc Clin Oncol Educ Book. 2015:e117-25. doi: 10.14694/EdBook_AM.2015.35.e117.

22.

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.

Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJ.

Breast Cancer Res Treat. 2015 Jun;151(3):501-13. doi: 10.1007/s10549-015-3414-3. Epub 2015 May 14.

PMID:
25971596
23.

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3356-7.

24.

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ.

Mol Oncol. 2015 Mar;9(3):586-600. doi: 10.1016/j.molonc.2014.10.011. Epub 2014 Nov 11.

25.

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.

Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ.

Oncotarget. 2014 Oct 30;5(20):9864-76.

26.

Genome-based risk prediction for early stage breast cancer.

Adaniel C, Jhaveri K, Heguy A, Esteva FJ.

Oncologist. 2014 Oct;19(10):1019-27. doi: 10.1634/theoncologist.2014-0124. Epub 2014 Sep 3. Review.

27.

Gene signature-guided dasatinib therapy in metastatic breast cancer.

Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF.

Clin Cancer Res. 2014 Oct 15;20(20):5265-71. doi: 10.1158/1078-0432.CCR-14-0800. Epub 2014 Aug 29. Erratum in: Clin Cancer Res. 2015 Jun 1;21(11):2653.

28.

Leptomeningeal disease and breast cancer: the importance of tumor subtype.

Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A.

Breast Cancer Res Treat. 2014 Aug;146(3):477-86. doi: 10.1007/s10549-014-3054-z. Epub 2014 Jul 20. Review.

PMID:
25038877
29.

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.

Singh JC, Jhaveri K, Esteva FJ.

Br J Cancer. 2014 Nov 11;111(10):1888-98. doi: 10.1038/bjc.2014.388. Epub 2014 Jul 15. Review.

30.

Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.

Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju158. doi: 10.1093/jnci/dju158. Print 2014 Jul.

31.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 1;32(19):2100-8. doi: 10.1200/JCO.2013.54.0955. Epub 2014 May 5. Review.

PMID:
24799487
32.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP; American Society of Clinical Oncology.

J Clin Oncol. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5. Review.

PMID:
24799465
33.

Pertuzumab in the treatment of HER2+ breast cancer.

Jhaveri K, Esteva FJ.

J Natl Compr Canc Netw. 2014 Apr;12(4):591-8. Review.

PMID:
24717573
34.

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689. Epub 2014 Mar 26.

35.

Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D.

Cell Res. 2014 May;24(5):542-59. doi: 10.1038/cr.2014.37. Epub 2014 Mar 28.

36.

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM.

Oncologist. 2014 Mar;19(3):228-34. doi: 10.1634/theoncologist.2013-0286. Epub 2014 Feb 17.

37.

Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer.

Li Y, Li Y, Chen T, Kuklina AS, Bernard P, Esteva FJ, Shen H, Ferrari M, Hu Y.

Clin Chem. 2014 Jan;60(1):233-42. doi: 10.1373/clinchem.2013.211953. Epub 2013 Oct 21.

38.

Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

Wang-Johanning F, Li M, Esteva FJ, Hess KR, Yin B, Rycaj K, Plummer JB, Garza JG, Ambs S, Johanning GL.

Int J Cancer. 2014 Feb 1;134(3):587-95. doi: 10.1002/ijc.28389. Epub 2013 Sep 13.

39.

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, Perez A.

Oncologist. 2013 Jun;18(6):661-6. doi: 10.1634/theoncologist.2012-0129. Epub 2013 May 22.

40.

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.

Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L.

Br J Cancer. 2013 Feb 5;108(2):285-91. doi: 10.1038/bjc.2012.557. Epub 2013 Jan 8.

41.

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Breast Cancer Res Treat. 2013 Jan;137(2):631-6. doi: 10.1007/s10549-012-2374-0. Epub 2012 Dec 15.

42.

Effect of HER2 status on distant recurrence in early stage breast cancer.

Hess KR, Esteva FJ.

Breast Cancer Res Treat. 2013 Jan;137(2):449-55. doi: 10.1007/s10549-012-2366-0. Epub 2012 Dec 6.

43.

ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.

Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JÅ.

Breast Cancer Res. 2012 Nov 16;14(6):R148. doi: 10.1186/bcr3358.

44.

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):63-72. doi: 10.1007/s00280-012-1977-9. Epub 2012 Sep 28.

45.

Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.

Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM.

Mol Cancer Ther. 2012 Nov;11(11):2526-34. doi: 10.1158/1535-7163.MCT-12-0460. Epub 2012 Sep 12.

46.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

47.

Speech prosthesis aspiration.

Grosu HB, Esteva FJ, Jimenez CA, Morice RC.

Emerg Med J. 2013 Jan;30(1):85. doi: 10.1136/emermed-2012-201325. Epub 2012 Apr 15. No abstract available.

PMID:
22508194
48.

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.

Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5832-7. doi: 10.1073/pnas.1201105109. Epub 2012 Mar 28.

49.

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.

Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA.

Cancer. 2012 May 15;118(10):2603-14. doi: 10.1002/cncr.26565. Epub 2011 Oct 5.

50.

Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

Tian Y, Esteva FJ, Song J, Zhang H.

Mol Cell Proteomics. 2012 Jun;11(6):M111.011403. doi: 10.1074/mcp.M111.011403. Epub 2012 Feb 7.

Supplemental Content

Loading ...
Support Center